HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.

Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating levels of low-density lipoprotein (LDL) particles. PCSK9 acts mainly by enhancing degradation of the LDL receptor in the liver. Several gain-of-function and loss-of-function mutations in the PCSK9 gene have been identified and linked to hypercholesterolemia and hypocholesterolemia, respectively. Since the loss-of-function mutations in humans are associated with protection against coronary heart disease, and with no apparent deleterious effects, PCSK9 inhibition is becoming attractive as a new strategy for lowering LDL cholesterol (LDL-C) levels, particularly in combination with statins. Candidate patient populations for PCSK9 inhibition include those with familial hypercholesterolemia, patients at high risk of cardiovascular disease not controlled by statin therapy, and patients with poor tolerance or total intolerance to statin therapy. PCSK9 inhibition represents a very promising target for reducing LDL-C levels and decreasing the risk of atherosclerotic cardiovascular diseases, but human clinical trials will be crucial to assess the potency and safety of PCSK9 inhibitors.
AuthorsMichel Farnier
JournalAmerican journal of cardiovascular drugs : drugs, devices, and other interventions (Am J Cardiovasc Drugs) Vol. 11 Issue 3 Pg. 145-52 (Jun 01 2011) ISSN: 1179-187X [Electronic] New Zealand
PMID21619378 (Publication Type: Journal Article, Review)
Chemical References
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Serine Endopeptidases
Topics
  • Animals
  • Anticholesteremic Agents (pharmacology)
  • Atherosclerosis (etiology, prevention & control)
  • Cardiovascular Diseases (etiology, prevention & control)
  • Cholesterol, LDL (blood, drug effects)
  • Drug Delivery Systems
  • Humans
  • Hyperlipidemias (drug therapy, genetics, physiopathology)
  • Mice
  • Mutation
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Serine Endopeptidases (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: